title: Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.
abstract: Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
authors: Section of Cardiovascular Medicine, Yale University School of Medicine, USA.
authors: Maria
authors: M
authors: Volkova
authors: Raymond
authors: R
authors: Russell
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D054715:Cardiotoxins / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D006333:Heart Failure / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects*; D015995:Prevalence; D012307:Risk Factors; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D054715:Cardiotoxins; D004317:Doxorubicin; D015255:Idarubicin